Table 1. Baseline clinicodemographic, operative, and pathological characteristics of the study cohort.

Variables	N  = 185
Age (y)	53.84 ± 11.82
Sex (male:female)	127:58
Clinical “T” stage
cT1 + cT2	27 (14.7%)
cT3	79 (43.2%)
cT4	77 (42.1%)
Pathological “T” stage
pT0 + pT1 + pT2	42 (22.7%)
pT3	58 (31.35%)
pT4	85 (45.95%)
Pathological “N” stage
pN0	55 (29.7%)
pN+	130 (70.3%)
Perioperative chemotherapy
Yes	71 (38.4%)
No	114 (61.6%)
Greater curvature tumors
Yes	105 (56.8%)
No	80 (43.2%)
Subtotal vs total gastrectomy
Subtotal	122 (65.9%)
Total	63 (34.1%)
Completeness of the resection
R0	159 (86%)
R1 + R2	26 (14%)
Tumor size (cm)	4.47 ± 2.63
Tumor depth (cm)	1.18 ± 0.69
Lymphovascular invasion
Yes	54 (29.4%)
No	131 (70.6%)
Perineural invasion
Yes	110 (59.5%)
No	75 (40.5%)
Perinodal extension
Yes	22 (11.9%)
No	163 (88.1%)
Omental metastasis
Yes	20 (10.8%)
No	165 (89.2%)
Signet ring cell tumor
Yes	14 (7.6%)
No	171 (92.4%)
Histological grade of the tumor
Well/moderately differentiated	74 (40.0%)
Poorly differentiated	111 (60.0%)
Recurrence
Yes	56 (30.3%)
No	129 (69.7%)
Peritoneal recurrence
Yes	33 (17.8%)
No	152 (82.2%)

Note: Values expressed as n (%) or mean ± SD.